… Drug therapy of these non motor symptoms complicates long-term PD drug therapy due to
possible occurrence of drug … on the progression of disability in early Parkinson's disease. The …

… Data on active clinical trials of PD drug therapies were obtained from ClinicalTrials.gov
for analysis in this review. ClinicalTrials.gov provides information on publicly and privately …

… been the mainstay of therapy for Parkinson's disease but its long-… In addition, Parkinson's
disease is commonly thought to be … Developments in the genetics of Parkinson's disease may …

… of patients within 5 years of therapy. Other drugs include dopamine-receptor-agonists, …
-B) inhibitors, anticholinergics and adjuvant therapy with the antiviral drug and the N-methyl-…

… drugs and new technologies. In this Review, we focus on disease-modifying and symptomatic
therapies under development for PD. We review cellular therapies and repurposed drugs, …

… motor symptoms of Parkinson's disease (PD). … therapies to classical pharmaceutics. This
review will provide us updated information regarding the current drugs and non-drugs therapies …

… Parkinson’s disease (PD) is a neurodegenerative disease manifesting … Parkinson pandemic.
Advances in treatment are anticipated, but current approaches mainly rely on drug therapy …

… Conclusions: This study found a differential compliance and persistence across PD drug
therapies. The compliance rate for rasagiline was significantly higher than that for all of the …

… pallidus, subthalamic nucleus, and cerebral cortex, and the drugs could be acting differently
at each of these sites. Sometimes I think we are striatally fixated in Parkinson's disease. …

… We conducted a review of clinical trials of drug therapies for PD using trial data obtained from
… We also assessed active drug development projects that had completed one clinical phase …